MHRA guidance aligns on key measurements for a registration trial, including primary endpoint and trial design elements
IND for phase 2b/3 trial submitted to the FDA
Axcella to host a conference call Tuesday, January 24 at 8:00 a.m. ET; To register, click here
https://finance.yahoo.com/news/axcella-announces-regulatory-path-registration-211500566.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.